Barinthus Biotherapeutics
A UK biotechnology company developing T-cell immunotherapies and viral-vector vaccines for infectious diseases, cancer and autoimmune conditions.
Last updated August 25, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Barinthus Biotherapeutics plc is a United Kingdom biotechnology company focused on developing immunotherapies and vaccines. The company operates as a clinical-stage biotechnology business whose research portfolio addresses infectious diseases, cancer and autoimmune conditions, including hepatitis B, human papillomavirus and prostate cancer. Its principal scientific emphasis is on stimulating or directing cellular immune responses, particularly T-cell responses, rather than relying exclusively on conventional antibody-based protection. The business was established in 2016 as a spin-off from research at the University of Oxford's Jenner Institute. Its founders were Sarah Gilbert and Adrian V. S. Hill, scientists associated with the development of vaccine technologies at Oxford. The company was originally named Vaccitech plc and was supported by a group of institutional and strategic investors, including Oxford Sciences Innovation, M&G Catalyst and GV, as well as international investment organizations. The company later broadened its identity and in November 2023 announced that it had adopted the Barinthus Biotherapeutics name. Barinthus's technology base includes the Chimpanzee Adenovirus Oxford platform, commonly known as ChAdOx, and Modified vaccinia Ankara, or MVA. These viral-vector systems are designed to imitate aspects of viral infection in human cells without causing the targeted disease, thereby presenting antigens and eliciting immune responses involving both antibodies and T cells. The company also describes synthetic SNAP platforms, including SNAP-TI for tolerance-inducing immunotherapy and SNAP-CI for cancer immunotherapy. These systems were previously discussed collectively under the SNAPvax name. The company's most prominent public association arose during the COVID-19 pandemic. In early 2020, Vaccitech and the University of Oxford co-invented a COVID-19 vaccine candidate using the ChAdOx platform. The resulting ChAdOx1 nCoV-19 candidate expressed the SARS-CoV-2 spike protein and entered clinical evaluation. Trial activity expanded internationally, with participants recruited in countries including Brazil, South Africa and the United States. A randomized controlled UK study of the candidate was reported in The Lancet in July 2020. This work made Vaccitech a visible participant in the global COVID-19 vaccine effort, although the company continued to present itself as a broader immunotherapy and vaccine developer rather than as a single-product vaccine business. Vaccitech completed an initial public offering in 2021 and began trading on the Nasdaq on 30 April of that year under the ticker BRNS. The later Barinthus rebranding was intended to distinguish the company from its earlier Vaccitech identity while retaining its underlying technology and development focus. As of 2024, the company employed more than 100 people. Its current positioning is that of an internationally oriented, clinical-stage biotechnology company using viral-vector and synthetic immune-modulation platforms to develop treatments and preventive products across several disease areas.
History
Barinthus Biotherapeutics originated in research conducted at the University of Oxford's Jenner Institute. In 2016, Sarah Gilbert and Adrian V. S. Hill helped establish the company as a university spin-off under the name Vaccitech plc. The venture was created to translate Oxford immunology and vaccine research into a broader development platform covering infectious diseases, cancer and autoimmune disorders. The company's early scientific identity was built around viral-vector technologies, especially ChAdOx and MVA. ChAdOx uses a chimpanzee adenovirus vector to deliver genetic instructions for a selected antigen, while MVA is a modified vaccinia-based vector. Both approaches are intended to generate immune responses that include antigen-specific T cells as well as antibodies. This made the platform relevant to therapeutic vaccines and cancer immunotherapy as well as conventional preventive vaccination. Vaccitech obtained financial backing and strategic support from multiple investors and organizations. Sources identify M&G Catalyst, GV, Fosun International, Tencent, Huawei, Sequoia Capital, GeneMatrix, Liontrust Asset Management, Korea Investment Partners and Oxford Sciences Innovation among its supporters. The company's portfolio included programs directed at conditions such as chronic hepatitis B, HPV-associated disease and prostate cancer, reflecting its focus on persistent infections and tumors in which cellular immunity may have therapeutic value. A defining period began in early 2020, when Vaccitech and the University of Oxford co-invented a COVID-19 vaccine candidate based on ChAdOx. The candidate, known as ChAdOx1 nCoV-19, used a chimpanzee adenovirus vector carrying genetic material for the SARS-CoV-2 spike protein. During 2020, clinical development expanded beyond the United Kingdom, with recruitment reported in Brazil, South Africa and the United States. A single-blind, randomized controlled trial conducted at five UK sites was reported in The Lancet in July 2020. The trial report described the candidate's immune response and safety assessment; some participants used prophylactic paracetamol to reduce adverse reactions. The pandemic program substantially increased public awareness of Vaccitech and the underlying Oxford technology. Nevertheless, the company retained a wider development strategy, continuing to work on immunotherapies and vaccines for infectious disease, oncology and immune-mediated conditions. Its technology portfolio later included two synthetic SNAP platforms: SNAP-TI, or SNAP-Tolerance Immunotherapy, and SNAP-CI, or SNAP-Cancer Immunotherapy. These platforms had previously been grouped under the SNAPvax designation and represented an expansion beyond the company's original viral-vector description. Vaccitech became a public company through an initial public offering in 2021. Its shares began trading on the Nasdaq on 30 April 2021 under the symbol BRNS. In November 2023, the company announced a corporate name change to Barinthus Biotherapeutics plc. The rebranding marked a change in corporate identity rather than a departure from its Oxford-derived technology base. As of 2024, the company had more than 100 employees and remained an active biotechnology developer headquartered in Oxford, with programs aimed at infectious diseases, cancer and autoimmune disease.
- 2023
Corporate name changed to Barinthus Biotherapeutics
[1]The company announced in November that Vaccitech plc would be renamed Barinthus Biotherapeutics plc.
- 2021
Initial public offering on Nasdaq
[1]Vaccitech completed its initial public offering and began Nasdaq trading on 30 April under the ticker BRNS.
- 2020
ChAdOx COVID-19 vaccine candidate developed
[1]Vaccitech and the University of Oxford co-invented a SARS-CoV-2 vaccine candidate using the ChAdOx viral-vector platform.
- 2020
ChAdOx1 nCoV-19 enters international clinical testing
[1]Recruitment for clinical evaluation was reported in the United Kingdom, Brazil, South Africa and the United States.
- 2016
Company founded as an Oxford University spin-off
[1]Vaccitech was established from research associated with the Jenner Institute at the University of Oxford, with Sarah Gilbert and Adrian V. S. Hill identified as co-founders.
Products and positioning
Clinical-stage biotechnology company focused on T-cell immunotherapy, therapeutic vaccination and immune modulation for infectious diseases, cancer and autoimmune conditions.
Viral-vector platform
ChAdOx
The Chimpanzee Adenovirus Oxford platform uses a chimpanzee adenovirus vector to present selected antigens to the immune system. It is designed to mimic aspects of viral infection while inducing both antibody and T-cell responses. The platform supported the company's COVID-19 vaccine work and is part of its broader approach to preventive and therapeutic vaccination.
Viral-vector platform
Modified vaccinia Ankara (MVA)
MVA is a modified vaccinia-based viral vector used to deliver antigenic material and stimulate cellular immunity. Barinthus presents it alongside ChAdOx as a platform capable of eliciting T-cell and antibody responses against pathogens and tumors. Specific commercial products and launch dates for the platform are not established in the supplied material.
Tolerance-inducing immunotherapy platform
SNAP-TI
SNAP-TI, short for SNAP-Tolerance Immunotherapy, is a synthetic platform intended to develop immune-modulating treatments for conditions in which selective tolerance may be therapeutically useful. It forms part of the company's expansion beyond viral-vector vaccines. The supplied sources do not provide a complete list of clinical products or development stages based on this platform.
Cancer immunotherapy platform
SNAP-CI
SNAP-CI, short for SNAP-Cancer Immunotherapy, is a synthetic immunotherapy platform aimed at cancer applications. It was previously discussed together with SNAP-TI under the SNAPvax designation. The platform reflects Barinthus's focus on directing immune responses against tumors, although detailed product-level information is not included in the supplied reference material.
Immunotherapy candidate
VTP-300
VTP-300 is identified as one of Barinthus Biotherapeutics' flagship offerings. The supplied material does not provide sufficient detail to describe its indication, mechanism, development phase or launch status without risking unsupported claims.
Immunotherapy candidate
VTP-200
VTP-200 is identified as one of the company's flagship offerings. Specific information about its target disease, technology, clinical status and commercial availability is not established in the supplied sources.
Brand decisions
2023
Rebrand Vaccitech as Barinthus BiotherapeuticsStrategyBackground
The company had expanded its identity beyond the Vaccitech name associated with its earlier vaccine work and broadered its platform description to include cancer and tolerance immunotherapies.
Action taken
In November 2023, Vaccitech plc announced that it would operate as Barinthus Biotherapeutics plc.
Aftermath
The company continued under the Barinthus Biotherapeutics name while retaining its Oxford-derived immunotherapy and vaccine focus.
2021
List the company on NasdaqOtherBackground
Vaccitech sought public-market access while developing vaccines and immunotherapies.
Action taken
The company completed an initial public offering and began trading on Nasdaq on 30 April 2021 under BRNS.
Aftermath
Vaccitech became a publicly listed biotechnology company.
2020
Advance the ChAdOx1 COVID-19 vaccine candidate into clinical testingProduct launchBackground
The emergence of COVID-19 created an urgent need for vaccine candidates, and Vaccitech's ChAdOx platform could be adapted to express the SARS-CoV-2 spike protein.
Action taken
Vaccitech worked with the University of Oxford on the ChAdOx1 nCoV-19 candidate and supported clinical evaluation in the United Kingdom and internationally.
Aftermath
The program became the company's most visible public project during the pandemic and generated clinical trial reporting in The Lancet.
Recent events
- 2023
Vaccitech announces rebranding as Barinthus Biotherapeutics[1]
Other
In November 2023, the company announced that Vaccitech plc would adopt the Barinthus Biotherapeutics name.
- 2021
Vaccitech completes Nasdaq initial public offering[1]
Other
The company completed its initial public offering and began trading on Nasdaq on 30 April 2021 under the ticker BRNS.
- 2020
Vaccitech and Oxford researchers co-invent a COVID-19 vaccine candidate[1]
Product launch · Other
Vaccitech and the University of Oxford developed a SARS-CoV-2 vaccine candidate using the ChAdOx viral-vector platform.
- 2020
International clinical recruitment expands for the ChAdOx1 COVID-19 vaccine candidate[1]
Other
Clinical trial recruitment for the ChAdOx1 nCoV-19 candidate included sites and participants in Brazil, South Africa and the United States, alongside UK trials.
Sources3 sources
Cite this profile: Cite the canonical profile. /brand-wiki/barinthus-biotherapeutics · Editorial policy · How profiles are compiled